UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss including noncontrolling interests in subsidiaries	$ (120,756)	$ (143,899)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash used in operating activities:
Change in fair value of investment, net	0	2,752
Gain on sale of investment	0	(3,591)
Depreciation and amortization	6,777	4,547
Amortization of debt discount and issuance costs	56	(178)
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	5,151	14,463
Change in fair value of Series A warrants	1,494	11,824
Change in fair value of Series B warrants	403	178,198
Compensation expense for share-based awards	2,257	979
Loss on foreign currency exchange	2,627	176
Change in fair value of equity securities	229,850	(49,007)
Gain on sale of equity securities	(78,374)	(15,436)
Earnings on equity investment in joint venture	(42,085)	(2,737)
Deferred income taxes	(15,500)	0
Changes in assets and liabilities:
Accounts receivable	(4,339)	(12,244)
Inventories	(3,125)	0
Prepaid expenses and other assets	(3,135)	(627)
Accounts payable and accrued expenses	723	2,826
Royalties and contingent legal fees payable	118	3,927
Deferred revenue	305	0
Net cash used in operating activities	(17,553)	(8,027)
Cash flows from investing activities:
Patent acquisition	(5,000)	(11,000)
Sale of investment at fair value	0	3,591
Purchases of equity securities	(107,537)	(27,871)
Sales of equity securities	191,494	33,467
Distributions received from equity investment in joint venture	0	1,830
Purchases of property and equipment	(410)	(45)
Net cash provided by (used in) investing activities	78,547	(28)
Cash flows from financing activities:
Repurchase of common stock	(39,508)	0
Issuance of Senior Secured Notes, net of lender fee	0	80,000
Paydown of Senior Secured Notes	(65,000)	(50,000)
Dividend on Series A Redeemable Convertible Preferred Stock	(1,399)	(523)
Taxes paid related to net share settlement of share-based awards	(503)	0
Proceeds from exercise of stock options	0	94
Net cash (used in) provided by financing activities	(106,410)	29,571
(Decrease) increase in cash and cash equivalents and restricted cash	(45,416)	21,516
Cash and cash equivalents and restricted cash, beginning	309,361	200,546
Cash and cash equivalents and restricted cash, ending	263,945	222,062
Supplemental schedule of cash flow information:
Interest paid	4,879	2,340
Income taxes paid	37	9
Noncash investing and financing activities:
Patent acquisition in exchange of notes receivable	0	4,000
Patent acquisition accrued liabilities	0	15,000
Distribution to noncontrolling interests in subsidiaries	$ 0	$ 906